JP2010523722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523722A5 JP2010523722A5 JP2010503269A JP2010503269A JP2010523722A5 JP 2010523722 A5 JP2010523722 A5 JP 2010523722A5 JP 2010503269 A JP2010503269 A JP 2010503269A JP 2010503269 A JP2010503269 A JP 2010503269A JP 2010523722 A5 JP2010523722 A5 JP 2010523722A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- group
- trail
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 64
- 239000003446 ligand Substances 0.000 claims description 40
- 230000006907 apoptotic process Effects 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000000411 inducer Substances 0.000 claims description 36
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 35
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 125000003107 substituted aryl group Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 150000001717 carbocyclic compounds Chemical class 0.000 claims description 26
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 16
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 16
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 16
- 239000000556 agonist Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 14
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
- 230000003463 hyperproliferative effect Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 8
- 101150009046 Tnfrsf1a gene Proteins 0.000 claims description 8
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000006242 amine protecting group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000006882 induction of apoptosis Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010000050 Abdominal adhesions Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000013058 Weber syndrome Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 201000007293 brain stem infarction Diseases 0.000 claims description 2
- 150000001735 carboxylic acids Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000001969 hypertrophic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 29
- -1 hydrogen compound Chemical class 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 0 CC(*)C*(*)C(*[C@@](C*(*)CC[C@@](CC1)*2[C@]1IC)C2=O)=O Chemical compound CC(*)C*(*)C(*[C@@](C*(*)CC[C@@](CC1)*2[C@]1IC)C2=O)=O 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92334807P | 2007-04-13 | 2007-04-13 | |
| US60/923,348 | 2007-04-13 | ||
| PCT/US2008/060215 WO2008128171A2 (en) | 2007-04-13 | 2008-04-14 | Diazo bicyclic smac mimetics and the uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523722A JP2010523722A (ja) | 2010-07-15 |
| JP2010523722A5 true JP2010523722A5 (https=) | 2012-04-19 |
| JP5416089B2 JP5416089B2 (ja) | 2014-02-12 |
Family
ID=39864640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503269A Active JP5416089B2 (ja) | 2007-04-13 | 2008-04-14 | ジアゾ二環式ｓｍａｃ模倣物およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8278293B2 (https=) |
| EP (1) | EP2139490B1 (https=) |
| JP (1) | JP5416089B2 (https=) |
| KR (1) | KR101081685B1 (https=) |
| CN (1) | CN101686981B (https=) |
| AU (1) | AU2008240119B2 (https=) |
| BR (1) | BRPI0810522B8 (https=) |
| CA (1) | CA2683318C (https=) |
| CY (1) | CY1115735T1 (https=) |
| DK (1) | DK2139490T3 (https=) |
| EA (1) | EA017797B1 (https=) |
| ES (1) | ES2504216T3 (https=) |
| HR (1) | HRP20140885T1 (https=) |
| HU (1) | HUE024142T2 (https=) |
| IL (1) | IL201474A (https=) |
| MX (1) | MX2009011069A (https=) |
| NZ (1) | NZ580468A (https=) |
| PL (1) | PL2139490T3 (https=) |
| PT (1) | PT2139490E (https=) |
| SI (1) | SI2139490T1 (https=) |
| WO (1) | WO2008128171A2 (https=) |
| ZA (1) | ZA200907055B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| ES2643233T3 (es) * | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| CA2780130A1 (en) * | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| CN109485662B (zh) * | 2012-08-23 | 2021-12-21 | 密歇根大学董事会 | Iap蛋白的二价抑制剂和使用其的治疗方法 |
| US9546174B2 (en) | 2012-11-30 | 2017-01-17 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (IAP) antagonists |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MX2016001654A (es) | 2013-09-09 | 2016-05-02 | Halliburton Energy Services Inc | Activacion de composiciones de cemento con retardo de fraguado mediante el intercambio de retardante. |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6768522B2 (ja) * | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AU2017253560B2 (en) | 2016-04-20 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| EP3697816A1 (en) | 2017-10-19 | 2020-08-26 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| EP3765026A4 (en) | 2018-03-10 | 2021-12-22 | Yale University | BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| IL281188B2 (en) | 2018-09-07 | 2025-08-01 | Arvinas Operations Inc | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| US20220096436A1 (en) | 2019-01-17 | 2022-03-31 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| EP3947368B1 (en) | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| CN110028508B (zh) * | 2019-05-16 | 2021-05-28 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| PH12022550721A1 (en) | 2019-09-25 | 2024-05-13 | Debiopharm Int Sa | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| WO2022056368A1 (en) | 2020-09-14 | 2022-03-17 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| AU2022239717A1 (en) | 2021-03-15 | 2023-11-02 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2024022275A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| AR131299A1 (es) * | 2022-12-09 | 2025-03-05 | Debiopharm Int Sa | Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2026006700A1 (en) * | 2024-06-28 | 2026-01-02 | Regents Of The University Of Michigan | Pyrrolo[1,2-a]-azocine analogues as iap antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| BRPI0506883A (pt) * | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| WO2006010119A2 (en) | 2004-07-09 | 2006-01-26 | Michael Norris | Cargo retaining device for use in vehicle cargo storage areas |
| WO2006010118A2 (en) * | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| NZ572531A (en) * | 2006-05-05 | 2011-09-30 | Univ Michigan | Bivalent smac mimetics and the uses thereof |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| US8445473B2 (en) * | 2008-04-11 | 2013-05-21 | The Regents Of The University Of Michigan | Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof |
| US8625740B2 (en) * | 2011-04-14 | 2014-01-07 | Morpho Detection, Inc. | System and method for correcting X-ray diffraction profiles |
-
2008
- 2008-04-14 WO PCT/US2008/060215 patent/WO2008128171A2/en not_active Ceased
- 2008-04-14 JP JP2010503269A patent/JP5416089B2/ja active Active
- 2008-04-14 ES ES08745750.3T patent/ES2504216T3/es active Active
- 2008-04-14 MX MX2009011069A patent/MX2009011069A/es active IP Right Grant
- 2008-04-14 KR KR1020097023384A patent/KR101081685B1/ko active Active
- 2008-04-14 US US12/159,249 patent/US8278293B2/en active Active
- 2008-04-14 BR BRPI0810522A patent/BRPI0810522B8/pt not_active IP Right Cessation
- 2008-04-14 NZ NZ580468A patent/NZ580468A/en not_active IP Right Cessation
- 2008-04-14 SI SI200831285T patent/SI2139490T1/sl unknown
- 2008-04-14 CN CN2008800186484A patent/CN101686981B/zh not_active Expired - Fee Related
- 2008-04-14 CA CA2683318A patent/CA2683318C/en active Active
- 2008-04-14 HR HRP20140885AT patent/HRP20140885T1/hr unknown
- 2008-04-14 PL PL08745750T patent/PL2139490T3/pl unknown
- 2008-04-14 AU AU2008240119A patent/AU2008240119B2/en not_active Ceased
- 2008-04-14 EP EP08745750.3A patent/EP2139490B1/en active Active
- 2008-04-14 DK DK08745750.3T patent/DK2139490T3/da active
- 2008-04-14 EA EA200901400A patent/EA017797B1/ru unknown
- 2008-04-14 HU HUE08745750A patent/HUE024142T2/en unknown
- 2008-04-14 PT PT87457503T patent/PT2139490E/pt unknown
-
2009
- 2009-10-09 ZA ZA2009/07055A patent/ZA200907055B/en unknown
- 2009-10-12 IL IL201474A patent/IL201474A/en active IP Right Grant
-
2012
- 2012-07-25 US US13/557,804 patent/US8664212B2/en not_active Expired - Fee Related
-
2014
- 2014-09-29 CY CY20141100792T patent/CY1115735T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523722A5 (https=) | ||
| CA2683318A1 (en) | Diazo bicyclic smac mimetics and the uses thereof | |
| EP1838320B1 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
| JP6708130B2 (ja) | キノリン誘導体 | |
| US7709664B2 (en) | Coumarin derivatives useful as TNFα inhibitors | |
| JP2012504133A5 (https=) | ||
| JP2024521706A5 (https=) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| TW201818937A (zh) | 治療癌症之方法 | |
| JP2020506951A5 (https=) | ||
| CA2854836C (en) | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | |
| JP2011500638A5 (https=) | ||
| JP2014526492A5 (https=) | ||
| CN1960731A (zh) | 调节炎性和转移过程的方法 | |
| CN1312810A (zh) | 作为磷酸二酯酶4抑制剂的取代1,8－二氮杂萘－4(1h)－酮类化合物 | |
| JP2020517598A5 (https=) | ||
| RU2014100744A (ru) | Лечение респираторных нарушений с помощью trpa1 антагонистов | |
| JP7768880B2 (ja) | Ｅｚｈ２を阻害するためのキノリン化合物および組成物 | |
| WO2012047630A2 (en) | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use | |
| JP2020531454A5 (https=) | ||
| WO2023212244A1 (en) | Methods of treating 5ht2a receptor-mediated conditions | |
| CA2505874A1 (en) | Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease | |
| JP2010540649A5 (https=) | ||
| JP2011519845A5 (https=) | ||
| JP2014526526A5 (https=) |